Center for Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Transfusion. 2023 Nov;63(11):2152-2158. doi: 10.1111/trf.17545. Epub 2023 Sep 12.
Noninvasive fetal RHD genotyping has been provided to nonimmunized RhD-negative pregnant women to guide anti-D prophylaxis. Among the Chinese, more than 30% of the RhD-negative phenotype is associated with variant RHD alleles, which would limit the accuracy of fetal RHD status prediction; thus, more targeting and proper programs need to be developed.
Fluorescence quantitative polymerase chain reaction PCR (qPCR) or Sanger sequencing on all RHD exons was used to detect maternal RHD genotypes. For pregnant women with RHD01N.01 or RHD01N.03 alleles, the presence of RHD exons 5 and 10 in cell-free DNA was determined by qPCR. For pregnant women with the RHD(1227G>A) allele, high-throughput sequencing on exon 9 of the RHD gene and RHCE gene was used to predict fetal RhD phenotype.
Among 65 cases of Chinese pregnant women with the serologic RhD-negative phenotype, three major genotypes were identified: RHD01N.01/RHD01N.01 (61.5%), RHD01N.01/RHD(1227G>A) or RHD01N.03/RHD(1227G>A) (20%), and RHD01N.01/RHD01N.03 (13.8%), along with three cases of minor genotypes (4.6%). For 43 pregnant women with the RHD01N.01 or RHD01N.03 alleles, qPCR on maternal cell-free DNA yielded a 98.5% (42/43) accuracy rate and 100% successful prediction rate. High-throughput sequencing was successfully used to predict fetal RhD phenotypes for 13 pregnant women with RHD(1227G>A).
On the basis of maternal RHD genotyping, fetal genotyping through qPCR or high-throughput sequencing can improve the accuracy and success rate of prenatal fetal RhD phenotype prediction among Chinese pregnant women. It plays a potential role in guiding anti-D prophylaxis and pregnancy management in Chinese pregnant women.
非侵入性胎儿 RhD 基因分型已为非免疫 RhD 阴性孕妇提供,以指导抗-D 预防。在中国,超过 30%的 RhD 阴性表型与变异 RHD 等位基因相关,这将限制胎儿 RhD 状态预测的准确性;因此,需要制定更有针对性和适当的方案。
使用荧光定量聚合酶链反应(qPCR)或 Sanger 测序对所有 RHD 外显子进行检测,以确定母亲的 RHD 基因型。对于 RHD01N.01 或 RHD01N.03 等位基因的孕妇,通过 qPCR 检测游离 DNA 中是否存在 RHD 外显子 5 和 10。对于 RHD(1227G>A)等位基因的孕妇,使用 RHD 基因和 RHCE 基因的高通量测序来预测胎儿 RhD 表型。
在 65 例中国 RhD 阴性表型孕妇中,鉴定出三种主要基因型:RHD01N.01/RHD01N.01(61.5%)、RHD01N.01/RHD(1227G>A)或 RHD01N.03/RHD(1227G>A)(20%)和 RHD01N.01/RHD01N.03(13.8%),以及三种次要基因型(4.6%)。对于 43 例 RHD01N.01 或 RHD01N.03 等位基因的孕妇,母体游离 DNA 的 qPCR 检测准确率为 98.5%(42/43),成功率为 100%。高通量测序成功用于预测 13 例 RHD(1227G>A)孕妇的胎儿 RhD 表型。
在母体 RHD 基因分型的基础上,通过 qPCR 或高通量测序进行胎儿基因分型,可提高中国孕妇产前胎儿 RhD 表型预测的准确性和成功率。这在中国孕妇抗-D 预防和妊娠管理中具有潜在作用。